← Leaderboards
Peter Ganz
Brigham And Women'S Hospital
$8,034,092
Attributed
$17,038,841
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,038,841 · 8
By mechanism
R01$11,860,839 · 4
P50$3,044,954 · 2
U01$1,859,218 · 1
P01$273,830 · 1
Top collaborators
- Ruth Dubin13 shared
- Rajat Deo9 shared
- Steven R Cummings6 shared
- Jorge R Kizer6 shared
- Anne B Newman6 shared
- Russell P Tracy6 shared
- Matthew S Freiberg4 shared
- Priscilla Y. Hsue4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Annaswamy Raji$1,157,374
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesProteinsMortalityAptamerProteomicsPathway InteractionsCohortBaseBiological MarkersCardiovascular Risk FactorCardiovascular SystemCardiovascular Disorder RiskRaceAtherosclerosisHeart FailureCoronary Heart DiseasePathway AnalysisParticipantEventProtein BiomarkersBiologicalRisk FactorsPlayInvestigation
Grant awards (34)
Elucidating the Biology of Cardiovascular Risk in Hemodialysis Patients Using Proteomics$732,468
R01 · FY2024 · HL
Proteomics of Cardiovascular Risk: The Multiethnic Study of Atherosclerosis$569,975
R01 · FY2024 · HL · contact PI
Elucidating the Biology of Cardiovascular Risk in Hemodialysis Patients Using Proteomics$721,496
R01 · FY2023 · HL
Proteomics of Cardiovascular Risk: The Multiethnic Study of Atherosclerosis$562,664
R01 · FY2023 · HL · contact PI
Elucidating the Biology of Cardiovascular Risk in Hemodialysis Patients Using Proteomics$801,559
R01 · FY2022 · HL
Proteomics of Cardiovascular Risk: The Multiethnic Study of Atherosclerosis$569,270
R01 · FY2022 · HL · contact PI
Elucidating the Biology of Cardiovascular Risk in Hemodialysis Patients Using Proteomics$1,140,149
R01 · FY2021 · HL
Proteomics of Cardiovascular Risk: The Multiethnic Study of Atherosclerosis$717,697
R01 · FY2021 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2020 · AG
Identifying Modifiable Biomarkers/Mediators for Cardiovascular Disease in Chronic Kidney Disease$320,000
U01 · FY2020 · DK · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$698,276
R01 · FY2019 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2019 · AG
Identifying Modifiable Biomarkers/Mediators for Cardiovascular Disease in Chronic Kidney Disease$146,168
U01 · FY2019 · DK · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$711,851
R01 · FY2018 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2018 · AG
Identifying Modifiable Biomarkers/Mediators for Cardiovascular Disease in Chronic Kidney Disease$349,999
U01 · FY2018 · DK · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$699,392
R01 · FY2017 · HL
Identifying Modifiable Biomarkers/Mediators for Cardiovascular Disease in Chronic Kidney Disease$692,874
U01 · FY2017 · DK · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2017 · AG
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins - SUPPLEMENT$4,925
R01 · FY2017 · AG
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$756,117
R01 · FY2016 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2016 · AG
Project 5: Cardiovascular Assessment ofthe Effects of Tobacco and Nicot p341-385$578,790
P50 · FY2016 · CA · contact PI
Identifying Modifiable Biomarkers/Mediators for Cardiovascular Disease in Chronic Kidney Disease$350,177
U01 · FY2016 · DK · contact PI
Project 5: Cardiovascular Assessment ofthe Effects of Tobacco and Nicot p341-385$610,403
P50 · FY2015 · CA · contact PI
Project 5: Cardiovascular Assessment ofthe Effects of Tobacco and Nicot p341-385$462,723
P50 · FY2014 · CA · contact PI
Project 5: Cardiovascular Assessment ofthe Effects of Tobacco and Nicot p341-385$441,028
P50 · FY2013 · CA · contact PI
DETECTION AND MODULATION OF VULNERABLE ATHEROSCLEROTIC P$48,533
P50 · FY2006 · HL · contact PI
DETECTION AND MODULATION OF VULNERABLE ATHEROSCLEROTIC P$486,581
P50 · FY2005 · HL
BASIS OF ALTERED VASOREACTIVITY IN DISEASED ARTERIES$0
P01 · FY2002 · HL
DETECTION AND MODULATION OF THE VULNERABLE ATHEROSCLEROTIC PLAQUE$48,533
P50 · FY2001 · HL
BASIS OF ALTERED VASOREACTIVITY IN DISEASED ARTERIES$0
P01 · FY2001 · HL
DETECTION AND MODULATION OF THE VULNERABLE ATHEROSCLEROTIC PLAQUE$368,363
P50 · FY2000 · HL
BASIS OF ALTERED VASOREACTIVITY IN DISEASED ARTERIES$273,830
P01 · FY2000 · HL